

## Domestic production of Ac-225 using the experimental fast reactor Joyo



Yuto Sasaki, Shigetaka Maeda  
Japan Atomic Energy Agency




JAEA celebrates 20th  
anniversary in October 2025

---

# 1. Introduction of JAEA

- R&D on advanced reactors by utilizing Joyo, HTTR and related facilities
- R&D on Fukushima Daiichi NPP decommissioning and radioactive waste management

JRR-3  
(Japan Research Reactor-3)



Experimental Fast Reactor Joyo



R&D on Fast Reactor and its Fuel Cycle Technology

HTTR (High Temperature Engineering Test Reactor)



R&D on HTGR and Related Heat Application Technology



#### Stable energy supply

Enhancing resource efficiency and energy security

#### Reduction in environmental impact

Reduction of radioactive waste



Contributing to healthcare through cancer drug manufacturing

#### Production of Medical

#### Radioactive Isotope (RI)

Space and nuclear fusion development, basic physics support

Provision of fast neutron irradiation field




#### Harmonization with renewable energy

Compensation for power fluctuations by adjustable power supply


#### Contributing to carbon neutrality

Hydrogen production, high-temperature heat utilization (industrial use)

JAERI, the predecessor of JAEA, used to produce and distribute a variety of radioisotopes domestically



The catalog of Radioisotopes from the JAERI era



## 1995 Cabinet Decision

- The production of medium- to long-lived radioisotopes that can be imported from overseas was discontinued.
- The production of industrial-use radioisotopes with stable and high demand was transferred to the private sector.





The JAEA's production of radioisotopes was limited to

- $^{60}\text{Co}$  (for industrial use)
- $^{192}\text{Ir}$  (for industrial and medical use)
- $^{198}\text{Au}$  (for medical use)




$^{198}\text{Au}$  for brachytherapy




$^{192}\text{Ir}$  for RALS  
(Remote After Loading System)

## 2. Medical radioisotope landscape in Japan

### Domestic utilization ratio of unsealed radioisotopes (2019)



### Number of unsealed radionuclide therapy



- Major Radioisotopes is becoming dependent on imports
- Expectations for Medical Radioisotopes is growing
- Western countries are ramping up medical radioisotopes production and research

31<sup>st</sup> May, 2022 Atomic Energy Commission, Japan

## Goals to be Achieved during next decade

- ① Establishment of a stable Radioisotope Diagnostic System through *partial domestic production of Mo-99/Tc-99m*
- ② Implementation of *Radioisotope Treatment Using Domestic Radioisotopes*
- ③ *Dissemination of Radioisotope Treatment* in Medical Setting
- ④ Making Radioisotope-Related Fields, centered on Medicine, as a *"Strength" of Japan*

## Contents of the Action Plan

- (1)Promoting initiatives for Domestic Production and Stable Supply of "Important Radioisotopes "
  - Strengthening R&D for mass production of **Ac-225** using "Joyo" and accelerators  
**(Production demonstration by JFY2026 with "Joyo")**
- (2)Establishment of systems and structure to promote utilization of radioisotopes in medical setting
- (3)Promoting R&D Contributing to Production of Radioisotopes
- (4)Strengthening Research Infrastructures, and Networks for Production and Utilization of Radioisotopes

### 3. Production methods of Ac-225 worldwide

### Existing method Th-229 generator



Extract Th-229 (Ac-225 generator)  
from U-233<sup>\*1</sup>



Ac-225 extracted from  
the Th-229 generator



Stable supply is possible  
Supply is limited

\*1 <https://isotopes.gov/BNL-AP-Hot-Cells>

\*2 <https://cycops.triumf.ca/homepage/opsphotos.htm>

\*3 <https://www.northstarnm.com/radiopharmaceutical-therapy/actinium-225/>

### Alternative method Accelerator method



High Power Cyclotron<sup>\*2</sup>  
(Th-232(p,x)Ac-225)



Middle Power Cyclotron / Rhodotron<sup>\*3</sup>  
(Ra-226(p,2n)Ac-225)



Linac<sup>\*4</sup>  
(Ra-226(γ,n)Ra-225→Ac-225)

High specific radioactivity and  
good handling

\*4 <https://www.raris.tohoku.ac.jp/facility/mikamine/%e5%a4%a7%e5%bc%b7%e5%ba%a6%e9%9b%b%e5%ad%90%e7%b7%9a%e5%bd%a2%e5%8a%a0%e9%80%9f%e5%99%a8/>

\*5 <https://neutrons.ornl.gov/hfir/>

### Alternative method Reactor method





Experimental Fast Reactor Joyo  
Fast Reactor  
(Ra-226(n,2n)Ra-225→Ac-225)



High Flux Isotope Reactor@ORNL<sup>\*5</sup>  
Light Water Reactor  
(Ra-226(3n,2β)Th-229  
→Ra-225→Ac-225)


Mass production is possible  
Scheduled annual-inspection shutdown

Advantages, Disadvantages




Long life generator  
Indirect production

Joyo's method




Hitachi's method



Direct production

QST's method



**HITACHI**  
Inspire the Next




Neptunium series

## 4. Ac-225 production at Joyo

- Joyo was constructed as experimental reactor of the first step of Fast Breeder Reactor development in Japan.
- It is used for a versatile of purposes, from fast reactor development and fundamental research to industrial applications.



Main specifications of Joyo	
Purpose	Development of <ul style="list-style-type: none"> <li>• Fast reactors</li> <li>• New fuel and material</li> </ul> <u>Production of medical radioisotopes</u>
Reactor type	Sodium cooled fast reactor
Fuel	MOX(Mixed Oxide) fuel
Thermal power	100MW
Core model	Cylinder (Diameter : 78cm, Height : 50cm)
Operation period	60 day/cy : 1~3cy/year




- FMF, which is connected to Joyo via sub-assembly (S/A) transportation route, is a large, heavily shielded, hot cell facility designed for remote examination of highly irradiated fast reactor (FR) fuel.
- It has various post irradiation examination (PIE) capabilities which have been applied for characterization of not only FR fuels irradiated in Joyo but also fuel debris retrieved from the TEPCO Fukushima Daiichi Nuclear Power Station.
- After Joyo restart, the fabrication of  $^{226}\text{Ra}$  target for irradiation in Joyo, and the chemical separation of  $^{225}\text{Ac}$  from irradiated  $^{226}\text{Ra}$  target will be carried out in FMF.

Appearance of FMF




PIE capabilities of FMF

Non destructive characterization	X-ray CT, Visual inspection, Profilometry, Gamma scanning, etc.
Destructive characterization	SEM/EPMA, TEM, SIMS, TIMS, XPS, etc.




Process of  $^{225}\text{Ac}$  production

1. Load  $^{226}\text{Ra}$  into a radioisotope production S/A
2. Irradiate the S/A with Joyo
3. Transport from Joyo to FMF (Through the underground)
4. The S/A is disassembled at the FMF
5. Chemical separation of  $^{225}\text{Ac}$



## Capable of meeting medical needs



### Medical needs

- 4 doses per patient at 8 weeks interval
- $100 \text{ kBq/kg-weight}^* \rightarrow 6 \text{ MBq / patient} (\div 60\text{kg})$

### Operation Pattern

- Irradiation : 45-day/cycle
- Fuel exchange and maintenance : 14-day/cycle
- Operation Cycle : 4 cycle/y

### Other conditions

- Ra-226 target : 1 g/cycle
- Milking interval : 1 week


↓

Milking	#1	#2	#3	#4	#5	#6~	Total	
						1cycle	Annual	
$^{225}\text{Ac}$ [GBq] (patient)	4.28 (710)	3.09 (520)	2.23 (370)	1.61 (270)	1.16 (190)	3.00 (500)	15.4 (2,560)	61.5

\* Clemens Kratochwil, Frank Bruchertseifer, et al. Targeted aTherapy of Metastatic Castration-Resistant Prostate Cancer with  $^{225}\text{Ac}$ -PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control, *J Nucl Med* 2018; 59:795-802


## 5. Procurement of Ra-226

Nuclides in radioactive equilibrium with Nat-Uranium



<i>Uranium series</i>	
<i>Nuclide</i>	<i>weight (g)</i>
$^{238}\text{U}$	$9.93 \times 10^{-5}$
$^{234}\text{U}$	$5.04 \times 10^{-1}$
$^{234}\text{Pa}$	$2.17 \times 10^{-10}$
$^{234m}\text{Pa}$	$2.17 \times 10^{-10}$
$^{234}\text{Th}$	$1.44 \times 10^{-5}$
$^{230}\text{Th}$	$1.48 \times 10^{-1}$
$^{226}\text{Ra}$	$3.09 \times 10^{-1}$
$^{222}\text{Rn}$	$1.98 \times 10^{-6}$
$^{218}\text{Po}$	$1.10 \times 10^{-9}$
$^{214}\text{Po}$	$9.51 \times 10^{-16}$
$^{210}\text{Po}$	$6.79 \times 10^{-5}$
$^{214}\text{Bi}$	$6.96 \times 10^{-9}$
$^{210}\text{Bi}$	$2.46 \times 10^{-6}$
$^{214}\text{Pb}$	$9.31 \times 10^{-9}$
$^{210}\text{Pb}$	$3.98 \times 10^{-3}$
$^{206}\text{Pb}$	$7.58 \times 10^{-1}$

Industrial use




Calibration source

Medical use




Therapeutic  
radiation source

In the 1920s



## Procurement from

### ① Discarded radiation sources




### ② Natural uranium mines



Production of new Ra-226 sources ceased in the 1960s, resulting in limited availability




It is necessary to recover Ra-226 from uranium mines




Uranium series

<sup>226</sup>Ra  
1600y



Actinium series

<sup>223</sup>Ra  
11.435d



Thorium series



<sup>228</sup>Ra  
5.75y

<sup>224</sup>Ra  
3.65d

Uranium-Thorium ore


## Purity of uranium or thorium ore

	Weight ratio(wt%)							
	A	B	C	D	E	F	G	H
$^{235}\text{U}$	99.7%	99.3%	98.8%	96.6%	90.1%	52.4%	40.3%	5.9%
$^{232}\text{Th}$	0.3%	0.7%	1.2%	3.4%	9.9%	47.6%	59.7%	94.1%
$^{228}\text{Ra}$	0.0004%	0.0009%	0.0016%	0.0046%	0.01%	0.12%	0.19%	2.0%
$^{226}\text{Ra}$	99.9%	99.9%	99.9%	99.9%	99.9%	99.8%	99.8%	97.9%




## Evaluation flow

Y. Sasaki, S. Maeda, "Effect of  $^{226}\text{Ra}$  purity as a target for  $^{225}\text{Ac}$  production using a fast reactor" *Journal of Radioanalytical and Chemistry*, Published online, 2024  
<https://doi.org/10.1007/s10967-024-09397-7>



① Discarded radiation sources



are preferable  
because  $^{228}\text{Ra}$  decays within  
about 60 years ( $2025\text{s} \rightarrow 1960\text{s}$ )

- Global competition for Ac-225 production is accelerating.
- JAEA is leveraging the fast reactor *Joyo* for large-scale radioisotope production.
- Regulatory milestones achieved in JFY2024 include obtaining a license for changes in reactor installation for radioisotope production.
- Discarded radiation sources from the 1960s promise to be a viable source for producing Ac-225 from Ra-226



- *Joyo* is scheduled to restart in JFY2026 with Ac225 production demonstration planned using discarded Ra-226 sources within the same FY.

**Thank you for your attention.**